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Wagner and MX. Birnstiel 
Research Institute of Molecular Pathology 
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INTRODUCTION 
The major obstacle to immunotherapy of cancer is the poor 
immunogenicity of tumors, especially in man. This is somewhat surprising 
since the large number of genetic alternations found in advanced cancers 
should give rise to peptide neo-epitopes capable of being recognized in the 
context of MHC-I molecules by cytotoxic lymphocytes (Lurquin et al., 1989). 
Indeed, tumor-associated (Groen et al., 1987) and tumor-specific antigens (van 
der Brüggen and van den Eynde, 1992) which should be targets for 
immunological attack have recently been identified. This leads to the 
suspicion that foreign antigens are indeed present on most, or at least many, 
tumor cells and that tumor cells are not rejected as foreign because the 
response of the immune system to the presented foreign antigen is inadequate 
(Fearon et al, 1990). 
If tumor-specific antigens can be identified on all or most kinds of tumors, 
it is conceivable that someday antibodies against the tumor antigens may be 
used to combat cancer of that recombinant antigens can be used to elicit 
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cellular immunity against tumors. Since to date the distribution and nature of 
tumor antigens is mainly unknown, attempts are being made to use the entire 
tumor cells, which were transfected with cytokine-expressing plasmids as a 
source of antigen and to rely on the immune system to seek out and to mount 
a response against such foreign antigens. 
It was found empirically (Fearon et al., 1990) that immunological tolerance 
of tumors can be broken by transfecting tumor cells with IL-2-gene expression 
vectors. When such cells are transplanted into syngeneic mice, a powerful -
systemic response based on T-lymphocytes is mounted by the organism leading 
to the destruction of both the IL-2 expressing tumor cells as well as parental 
tumor cells (not expressing cytokines) injected at distant sites. The systemic 
response does not derive from an increased systemic level of IL-2 as a 
consequence of implantation of cytokine producing tumor cells, rather it is the 
high level of cytokines arising locally, which is thought to have a dramatic 
effect on reprogramming the immune system. 
This initial observation has led to an avalanche of rather unsystematic 
studies for many mouse tumor models using different cytokine genes (reviewed 
by Zatloukal et al., 1993) in which rejection of parental tumor cells was 
reproduced using the above mentioned strategy. It is hoped that such findings 
will ultimately lead to clinical protocols in which the primary tumor will be 
removed from patients, the tumor cells set to culture, transfected with cytokine 
expression vectors, inactivated with X-rays and implanted as tumor vaccines 
back into patient. If a strong immune response results, one can be hopeful 
that this procedure will lead to an eradication of distant micrometastases over 
a long time which have arisen previously from disseminated tumor cells. 
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Transferrinfection of Tumor Cells for the Generation of Tumor Vaccines 
Since the tumor tissue may be heterogeneous due to tumor progression 
and selection by the host immune system, it may be desirable not to use 
transfected or transduced cell clones, as has been done in most experiments 
reported up to now (Zatloukal et al , 1993). This procedure, besides being 
time consuming and delaying unnecessarily the application of the "tumor 
vaccine" may inadvertently lead to selection of an unrepresentative cell clone. 
Furthermore, extensive culturing and expansion of cells may lead to a loss of 
the tumor antigen. A procedure by which the bulk of the tumor cells can be 
transfected soon after removal and culture would seem desirable. 
We believe that our recently developed adenovirus-augmented, receptor-
mediated DNA transfer technique "Adenovirus-Enhanced Transferrinfection" 
(AVET) (Cotten et a l , 1992, Curiel et a l , 1992, Wagner et al., 1992, Zatloukal 
et al., 1992) has many advantages over retroviral transduction or DNA 
transfection followed by clonal expansion of the genetically modified cells. 
AVE is a new transfection protocol in which the plasmid DNA to be 
transported into the tumor cells is reacted with transferrin-polylysine to form 
highly condensed round particles with a diameter of approx. 100 nm, referred 
to as "donuts" (Zatloukal et al., 1992). These "donuts" are linked to 
adenovirus Ad5dll014 which, owing to its endosomolytic property, greatly 
enhances the receptor-mediated transfer of genes into cells and ultimately into 
the cell nucleus (Cotten et al , 1992, Curiel et al., 1992, Wagner et all, 1992, 
Zatloukal et al., 1992). 
One of the outstanding features of AVET is that with this technique a 
multiplicity of DNA plasmids (per cell) can be introduced into a large fraction 
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of cells both from cell lines and primary cell culture, including freshly prepared 
murine and human melanoma cells. Followed transferrinfection, 
extraordinarily high levels of cytokine or reporter gene expression can be 
achieved routinely in freshly isolated tumor cells. Cytokine-expressing cells 
can then be easily mixed with non-transfected irradiated cells to obtain any 
desired cytokine-expressing level. This seems to be a good starting point for 
the generation of a tumor vaccine by the procedure described above. 
To test the concept of a tumor vaccine, we chose a murine melanoma skin 
cancer model. For several reasons, melanoma cancer seems to be a 
particularly interesting target: There is ample evidence that melanomas are 
subject to immunological control in humans. For instance, there is a 
(transient) regression of skin cancers in about 25% of the patients and 
complete remission in about 0.5%, and tumor-specific antigens (MAGE 1, 
MAGE 3) have been identified (van der Brüggen and van den Eynde, 1992; 
Gaugier et al., 1994). In addition, cytotoxic T-lymphocytes directed against the 
tumor can be obtained from patients (Herin et a l , 1987; Topallan et al., 1989). 
Immunization with IL-2 Transfected Melanoma Cells Protects Mice from 
Tumor Development 
The murine melanoma cell line Cloudman S91 (clone M3) was obtained 
from ATCC (No. CCL53.1). M3 cells which were established from a 
spontaneously developed melanoma in DBA/2 mice (Cloudman, 1941) express 
low level of MHC-I antigens (unpublished observation) and are only 
moderately immunogenic. 
Groups of 6 mice were immunized with IL-2 transfected (24,000 Units/106 
cells / 24 h), or non transfected tumor cells. Prior to immunization, cells were 
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irradiated (2,000 rad) to avoid further cell proliferation. Mice were 
immunized twice subcutaneously with 1 χ 105 cells into the left flank in a 
weekly interval. After an additional week, animals were challenged with 1 χ 
105 viable M3 melanoma (30-fold tumorigenic dose) cells into the right flank 
and tumor growth was scored weekly. 
Control animals which only received a challenge dose developed tumors 
within 2 weeks, whereas M3/IL-2 vaccinated mice were completely protected 
(fig. 1). 5 out of 6 animals which were immunized with non transfected 
melanoma cells developed tumors. Our results show that irradiation of tumor 
cells led to a somewhat slower tumor growth, but was not sufficient for the 
generation of an adequate immune response in our model. 
Vaccine: 
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Fig. 1. Groups of DBA/2 mice (each 6 animals) were vaccinated twice in a 
•one week interval with 1 χ 105 IL-2 transfected, irradiated M3 cells and 
challenged with 1 χ 105 viable M3 cells one week later. 
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AVET leads to very high cytokine expression levels with IL-2 Production 
rates in M3 cells in vitro of more than 60.000 Units/106 cells / 24 h. Since 
other groups used much lower cytokine levels for vaccination of animals, we 
were interested whether the high IL-2 production provides any advantage for 
vaccine efficiency. Vaccines which produced different amounts of IL-2 were 
generated by using transfection complexes in which the IL-2 expression vector 
(pWS2m) was mixed with plasmid missing the IL-2 coding region (pSP) in 
different ratios. This procedure allowed to adjust the IL-2 expression to 400 
Units/ 106 cells/ 24 h without changing the complex formation. 
Table 1. IL-2-dose dependent protection of immunized mice 
Challenge/ 1 w 2 vv 3 w 4 w 5 w 6 w 8 w 
IL-2-production 
1 χ ΙΟ 5 M3 
IL-2 high 
1 χ ΙΟ 5 Μ 
IL-2 low 
3 χ ΙΟ 5 M3 
IL-2 high 
3 χ ΙΟ 5 M3 
IL-2 low 
0/6 0/6 0/6 0/6 0/6 0/6 0/6 
0/5 0/5 1/5 1/5 1/5 1/5 1/5 
0/8 0/8 1/8 1/8 1/8 1/8 1/8 
0/8 1/8 5/8 5/8 5/8 5/8 5/8 
Table 1: Mice were immunized twice with 1 χ 105 IL-2 transfected, irradiated 
(2000 rad) M3 cells producing either 20.000-30.000 Units IL-2/ 106 cells / 24 
h (IL-2 high) or 400-500 Units IL-2/ 106 cells / 24 h (IL-2 low). One week 
after the second immunization, the mice were challenged with 1 χ 105 or 3 χ 
105 parental (tumorigenic) M3 cells. Numbers represent tumor bearing 
animals/total number of animals at the indicated periods after challenge. 
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Using this approach, mice were immunized twice with high and low level IL-2 
producing vaccines as described above. One week after the second 
immunization animals were challenged with either 1 χ 105 or 3 χ 105 wild-type 
M3 cells. 
We find that there is a dose-dependent relationship between IL-2 expression 
in vitro and vaccine efficiency in vivo. The low level IL-2 vaccine is less 
effective than the high level IL-2 vaccine: a lower cancer cell numbers are 
rejected, tumor development occurs earlier, and fewer animals show protection 
(Table 1). 
Fates of Cytokine-Transfected Tumor Cells In Vivo 
The Polymerase Chain Reaction (PCR) amplification technique with an 
appropriate internal standard for quantitative evaluation was adopted to 
determine the survival time of IL-2 plasmid and adenovirus DNA (another 
component of the transfection complex) of subcutaneously injected, 
transferrinfected and irradiated M3 cells. The persistence of the DNAs was 
taken as a measure for the survival of the cells at the vaccination site. Three 
groups of DBA/2 mice (two animals each) were injected with 3 χ 105 IL-2 
transfected, irradiated M3 cells. PCR analysis of the samples taken at day 
one, two and five after immunization shows a fast destruction of the IL-2 
plasmid after subcutaneous injection into the back of the mouse. While still 
detectable after 24 h and 48 h, the IL-2 plasmid could only be amplified from 
one DNA sample prepared from skin specimens than had been injected 5 days 
previously, the second DNA sample from day 5 was negative for IL-2. 
Adenovirus DNA could be successfully amplified from day 1 and day 2. 
However, both DNA samples from day 5 were completely negative (Figure 2). 
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The possible transfer of recombinant or viral DNAs to nearby lymph nodes, 
to different organs of the animals as well as monocytes and macrophages from 
the peripheral blood was investigated at high sensitivity. 12 male and 12 
female DBA/2 mice were injected with 1 χ 106 IL-2 transfected M3 cells. 24 
h and 48 h after injection, DNA from six animals of each group was prepared 
from peripheral blood cells and several organs. PCR analysis fails to disclose 
amplifiable IL-2 adenovirus DNA in all DNA samples from the various mouse 
organs including draining lymph nodes, spleen, kidney, lung, liver, colon, testis, 
ovaries, and the peripheral blood mononuclear cells. 
In order to determine systemic IL-2 levels following immunization, groups 
of 3 mice were injected with 1 χ 106, 3 xlO5 and 1 χ 105 IL-2 transfected M3 
cells which produced 46.000 Units IL-2/106 cells/24h in vitro. After 24 and 48 
h blood of animals was collected and IL-2 levels in sera were determined by 
ELISA (Genzyme, Cambridge, MA). As a result, after 24 h systemic levels 
became detectable in all three mice receiving 1 χ 106 cells, and in 1 out of 3 
mice receiving 3 χ 105 cells. Animals treated with 1 χ 105 IL-2 transfected 
cells, the dose which generates systemic protection, showed no systemic IL-2 
levels in the sera. At 48 h after cell implantation, systemic IL-2 was not 
detectable in any animal. These results are in line with the PCR analysis 
above, suggesting that M3 cells are rapidly eliminated after injection. 
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Fig. 2. PCR amplification of IL-2 plasmid from injection site: 3 χ 105 IL-2 
transfected cells were injected into DBA/2 mice. One, two and five days later, 
mice were sacrificed and immunization sites were excised. Tissues were 
incubated overnight in proteinase Κ buffer (50 mM Tris-HCl, 100 mM EDTA, 
100 mM NaCl, 1% SDS, 0.5 mg/ml proteinase K) at 55° C. DNA was 
extracted twice with phenol /CHC13 followed by isopropanol precipitation. The 
PCR cocktail contained 1 μg DNA, 1 χ PCR buffer (Boehringer Mannheim), 
3 Units Taq-Polymerase (Boehringer Mannheim), 1 mM of each dNTP, and 
25 pmol of specific primers. The conditions of standard PCR reaction were: 
5 min denaturation at 95° C, followed by 40 cycles each 30 sec at 94°, 30 sec 
at 60° and 1 min at 72° C. 
(Fig. 2a): As a control of IL-2 plasmid amplification (450 bp fragment), 1000 
copies of a deleted version of the IL-2 plasmid were added to each PCR 
reaction, resulting in lower bands on the gel (280 bp fragment). Primers were 
5 ' - G T C A A C A G C G C A C - C C A C T T C A A G C -3 ' ;5 ' -
GCTTGTTGAGATGATGCTTTGACA -3'. 
(Fig. 2b): Adenovirus amplification was proved by adding 1000 copies of 
adenovirus genome to the control reaction. Primers were 5' - GGTCCTGTG-
TCTGAACCTGAG-3'; 5' -TTATGGCCTGGGGCGTTTACA-3' (317 bp 
fragment). 
476 
DISCUSSION 
Our results clearly demonstrate that application of modified tumor cells 
expressing IL-2 at high levels leads to systemic and long-lasting protection 
against a challenge with highly tumorigenic cells. For modifying cancer cells 
with IL-2 genes, we have used a new gene delivery technique i.e. adenovirus-
enhanced transferrinfection (AVET), which combines the receptor-mediated 
endocytosis uptake mechanism with the endosome disruption activity of 
adenovirus. This technique allows to test the efficiency of cytokine-production 
by the modified tumor cell over a wide range of expression of cytokines as 
demonstrated in our murine model. Most studies with cytokine-expressing 
tumor cells so far were performed with either stably transfected cell line or 
retrovirally transduced cells producing significantly lower levels (100-3.500 
Units IL-2 /106 cells/24 h) than we routinely obtain. By using 
transferrinfection, transfected melanoma cells secrete up to 60.000 Units IL-
2/106 cells/24 hrs. Our results show, that low levels of IL-2 (around 400 Units/ 
106 cells/ 24 h) secreted from irradiated melanoma cells failed to protect 
completely. In contrast, the high production by the vaccine allowed to reject 
1 χ 105 parental melanoma cells in 100% of the immunized animals (see Table 
1)· 
In contrast to stable integration of genes which is obtained by retrovirus-
mediated transduction, AVET leads to long-term but transient expression of 
the delivered gene from episomally located DNA (Wagner et al., 1992). 
Besides persistence of gene expression, the survival of the cells after 
vaccination might be a limiting factor for application in humans since lethally 
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irradiated cells are applied. We therefore determined how long IL-2 has to 
be secreted and for how long the cells have to survive in vivo to induce an 
adequate immune response. Using PCR we detected amplifiable IL-2 or 
adenovirus DNA for 2 to animal 5 days after injection at the immunization 
site. These data indicate that neither transient cytokine expression nor 
irradiation is limiting for the induction of the immune system. Another 
important finding is that no IL-2 DNA nor adenovirus DNA is detectable in 
draining lymph nodes or other tissues. These data also show that modified 
tumor cells do not migrate and exclude the possibility of direct gene transfer 
into the germ line by the applied transfection and immunization procedure. 
AVET for the generation of "tumor vaccines" is not only restricted to 
melanoma cancer or to IL-2. Other specific targets like modified colon, liver, 
or renal tumor cells should also lead to enhanced immunogenicity against 
developing metastases when applied under the appropriate conditions. The 
general concept for the stimulation of the host immune system through 
elevated levels of cytokines produced at the immunization site seems to be 
more dependent on the ctyokine level than on the time period of exposure. 
Further experiments need to be done to investigate the host immune response 
to the induced cytokine expression and the resulting characterization of cells 
invading the tumor and the resulting change in the specific cytokine response 
at the immunization site will lead to further understanding the role of the 
induced ctyokine and the importance of high expression levels. 
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